Incidence of antiretinal antibodies in melanoma: Screening of 77 serum samples from 51 patients with American Joint Committee on Cancer stage I-IV

British Journal of Dermatology

Volumn 152, Issue 5, 2005, Pages 931-938

  Ladewig, G ^a   Reinhold, U ^a   Thirkill, C E ^b   Kerber, A ^a   Tilgen, W ^a   Pföhler, Claudia ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiretinal antibodies; Immunofluorescence; Melanoma associated retinopathy

Indexed keywords

CANCER ANTIBODY; CROSS REACTING ANTIBODY; EPITOPE; RETINA ANTIBODY; RETINA ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY SCREENING; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS REACTION; DISEASE ACTIVITY; FEMALE; GERMANY; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MELANOMA ASSOCIATED RETINOPATHY; PARANEOPLASTIC SYNDROME; PRIORITY JOURNAL; RETINOPATHY; SYMPTOM;

ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PARANEOPLASTIC SYNDROMES; RETINA; RETINAL DISEASES; TUMOR CELLS, CULTURED;

EID: 18944376832     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06480.x     Document Type: Article

References (17)

1. Milam AH, Saari JC, Jacobson SG et al. Autoantibodies against retinal bipolar cells in cutaneous melanoma-associated retinopathy. Invest Ophthalmol 1993; 34:91-100.
2. Keltner JL, Thirkill CE, Yip PT. Clinical and immunologic characteristics of melanoma-associated retinopathy patients. J Neuro Ophthalmol 2001; 21:173-87.
3. Potter MJ, Adamus G, Szabo SM et al. Autoantibodies to transducin in a patient with melanoma-associated retinopathy. Am J Ophthalmol 2002; 134:128-30.
4. Pföhler C, Haus A, Palmowski A et al. Melanoma-associated retinopathy: high frequency of subclinical findings in patients with melanoma. Br J Dermatol 2003; 149:74-8.
5. Abu-Shakra M, Buskila D, Ehrenfeld M et al. Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis 2001; 60:433-41.
6. Thirkill CE. Cancer-induced blindness. Lung Cancer 1996; 14:253-64.
7. Jampol LM, Kim HH, Bryar PJ et al. Multiple serious retinal detachments and subretinal deposits as the presenting signs of metastatic melanoma. Retina 2004; 24:320-2.
8. Haus AH, Palmowski AM, Pföhler C et al. Melanoma-associated retinopathy: screening for melanoma-associated retinopathy in patients with cutaneous mak'gnant melanoma. Neuro Ophthalmol 2002; 27:121-37.
9. Grus FH, Joachim SC, Hofmann EM, Pfeiffer N. Complex autoantibody repertoires in patients with glaucoma. Mol Vis 2004; 10:132-7.
10. Thirkill CE, Keltner JL, Morse LS et al. The incidence of 'normal antibody activity' with retina in a population of 100 normal individuals. Invest Opthomol Vis Sci 2004; 45:E-abstract 547.
11. Dumonde DC, Kasp-Grochowska E, Graham E et al. Anti-retinal autoimmunity and circulating immune complexes in patients with retinal vasculitis. Lancet 1982; ii:787-92.
12. Chan CC, Palestine AG, Nussenblatt RB et al. Anti-retinal auto-antibodies in Vogt-Koyanagi-Harada syndrome, Behçet's disease, and sympthetic ophthalmia. Ophthalmology 1985; 92:1025-8.
13. Thirkill CE. Retinal pigment epithelium hypersensitivity, an association with vision loss: RPE hypersensitivity complicating paraneo-plastic retinopathies. Ocul Immunol Inflamm 2000; 8:25-37.
14. Wolfensberger TJ, Aptsiauri N, Godley B et al. Antiretinal antibodies associated with cystoid macular edema. Klin Monatsbl Augenheilkd 2000; 216:283-5.
15. Jacobson DM, Adamus G. Retinal anti-bipolar cell antibodies in a patient with paraneoplastic retinopathy and colon carcinoma. Am J Ophthalmol 2001; 131:806-8.
16. Penfold PL, Provis JM, Furby JH et al. Autoantibodies to retinal astrocytes associated with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 1990; 228:270-4.
17. Hauschild A, Engel G, Brenner W et al. Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy. Br J Dermatol 1999; 140:1065-71.